New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
12:33 EDTCRM, DE, SKX, SQNM, ZLC, TLYS, STJOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday in a pre-holiday session marked by little corporate news but a fair amount of economic data. The averages opened quietly after the Labor Department reported a drop in first-time unemployment claims from the prior week, as expected. Among the other economic reports, the consumer confidence reading was slightly lower than expected and the leading economic indicators were slightly above expectations. There was little reaction to any of the reports and volume has been light, which is not surprising... ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 410,000, which was in-line with forecasts. Markit's "flash" November flash PMI rose to 52.4 from 51.0 in October. The final November reading of the University of Michigan Sentiment index slipped to 82.7 from its 84.9 preliminary reading. The leading indicators edged up 0.2% in October to 96.0 from 95.8 in September. In Europe, the region's finance ministers and the IMF were unable to reach a bailout agreement for Greece and will meet again on Monday with an eye on resolving the remaining disagreements. In Asia, Japanese exports fell 6.5% in October, which was worse than expectations of a 4.9% decline... COMPANY NEWS: Salesforce.com's (CRM) Q3 results beat on the top and bottom lines and RW Baird and Wells Fargo reiterated their Outperform ratings on the stock following the report. Shares advanced 8%. Conversely, Deere (DE) shares slumped 4% after its earnings missed expectations, as did its guidance for the coming year... MAJOR MOVERS: Among the notable gainers was Sketchers (SKX), rising 12% after Susquehanna upgraded the stock to Positive from Neutral, citing valuation and product momentum. Also higher were shares of Sequenom (SQNM), up 11% after a committee of the American College of Obstetricians and Gynecologists recommended that cell-free fetal DNA testing be offered to certain at-risk patients. Among the noteworthy losers following their earnings reports were Zale (ZLC), down over 28%, and Tilly's (TLYS), down 17%. Also lower was St. Jude Medical (STJ), which fell 14% after an FDA inspection report cited serious flaws in its oversight of design changes in its Durata line of defibrillator leads... INDICES: Near 12:30 pm ET, the Dow was up 45.14, or 0.35%, to 12,833.65; the Nasdaq was up 7.07, or 0.24%, to 2,923.75; and the S&P 500 was up 2.43, or 0.18%, to 1,390.24.
News For CRM;DE;SKX;SQNM;ZLC;TLYS;STJ From The Last 14 Days
Check below for free stories on CRM;DE;SKX;SQNM;ZLC;TLYS;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
10:26 EDTSKXOptions with decreasing implied volatility
Subscribe for More Information
09:16 EDTSKXOn The Fly: Pre-market Movers
Subscribe for More Information
July 23, 2014
16:18 EDTSKXSkechers reports Q2 EPS 68c, consensus 40c
Subscribe for More Information
15:30 EDTSKXNotable companies reporting after market close
Subscribe for More Information
07:45 EDTSTJSt. Jude Medical management to meet with Deutsche Bank
Subscribe for More Information
July 22, 2014
15:07 EDTCRMEarnings Preview: Microsoft to report after Nadella makes big job cuts
Subscribe for More Information
08:02 EDTSTJSt. Jude announces FlexAbility Ablation Catheter CE Mark approval, first use
St. Jude Medical CE Mark approval and first use of the FlexAbility Ablation Catheter. Designed with feedback from physician thought-leaders around the world, the FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design. The next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through its ability to bend and conform to the cardiac anatomy, decreasing the amount of pressure distributed to a patientís heart wall while simultaneously increasing the stability of therapy delivery.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.
July 16, 2014
18:03 EDTCRMCoca-Cola Enterprises may diversify into IT applications, WSJ says
Coca-Cola Enterprises (CCE) is planning on selling information products that it has developed for its internal use, says the Wall Street Journal. Coca-Cola Enterprises is developing an application on a Salesforce.com (CRM) platform that it may begin selling this year or next, added the Wall Street Journal. Reference Link
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
July 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
08:00 EDTSTJSt. Jude Medical management to meet with Leerink
Meeting to be held in New York on July 22 hosted by Leerink.
July 14, 2014
09:05 EDTSTJSt. Jude Medical to acquire NeuroTerm for approximately $200M in cash
St. Jude Medical has signed a definitive agreement to acquire privately held NeuroTherm, a manufacturer of interventional pain management therapies, for approximately $200M in cash. NeuroTherm is involved in the treatment of spinal pain using radiofrequency ablation, a segment of the chronic pain market in which St. Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately $10M-$15M to St. Jude Medicalís 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St. Jude Medicalís consolidated EPS in 2014 and accretive thereafter on a GAAP basis.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use